ADA: Merck, Pfizer's Steglatro rings up CV safety win but still lags heart-helping peers

Merck and Pfizer’s Steglatro, late to the SGLT2 party, has been working to catch up to its in-class rivals, which already bear heart-helping approvals. But its cardiovascular outcomes data won’t help it get on their level.